Summary:
Molbio Diagnostics’ IPO closed at 70.26x subscription, surging from 3.11x on Day 2, led by QIB demand at an extraordinary 186.39x. NII subscribed 49.80x, while retail and employee quotas reached 12.98x and 13.28x, respectively. Strong demand reflects investor interest in Molbio’s Truenat diagnostics platform and its global patent footprint. Shares are expected to list on August 17, 2026.
Molbio Diagnostics' IPO closed its bidding window on August 12, 2026, the final day of a three-day subscription period. The company develops and manufactures diagnostic testing devices used to detect infectious and other diseases, with its flagship Truenat platform, a portable testing machine that delivers results in about an hour. As of March 31, 2026, its portfolio covered 30 diseases through 43 assays, including tests for tuberculosis, COVID-19, HIV, hepatitis B and C, and HPV. The company's TB test is among the rapid molecular diagnostic tests recommended by the World Health Organization for initial detection of TB and rifampicin resistance, and its Truenat technology holds patent protection in more than 100 countries.
This is a ₹939.70 crore IPO, made up of a ₹200 crore fresh issue and an offer for sale of ₹739.70 crore. The fresh issue proceeds are earmarked for capital expenditure toward setting up infrastructure for a research and development facility and Centre of Excellence, to be operated by wholly owned subsidiary Bigtec, among other purposes, while the OFS portion goes to existing shareholders selling part of their stake.
Price band was ₹768 to ₹807 per share. Lot size is 18 shares, so retail investors needed ₹14,526 to apply at the upper end. Listing is expected August 17 on both BSE and NSE.
Molbio Diagnostics IPO - Day 3 Subscription Status
Day 2 had carried the issue to 3.11x overall. Demand accelerated dramatically through the final day, with the issue closing subscribed 70.26 times overall by the close of bidding.
Category-wise Breakdown on Day 3
| Category | Subscription (Final, as of 5:00 PM close) |
| Qualified Institutional Buyers (QIB) | 186.39x |
| Non-Institutional Investors (NII) | 49.80x |
| — Big NII (>₹10L) | 50.82x |
| — Small NII (₹2–10L) | 47.76x |
| Retail Individual Investors (RII) | 12.98x |
| Employees | 13.28x |
| Overall | 70.26x |
What Day 3 Numbers Indicate
QIB has driven this final-day surge in dramatic fashion, closing at an extraordinary 186.39x, a very strong signal of institutional conviction, since QIB investors typically place the bulk of their bids only once they've had time to assess how the rest of the book has filled up. NII followed with a very healthy close of 49.80x, with big HNIs (50.82x) marginally ahead of small HNIs (47.76x).
Retail and the employee quota both closed comfortably oversubscribed too, at 12.98x and 13.28x respectively, more measured than the institutional surge but still a strong showing.
The jump from 3.11x at Day 2's close to 70.26x by the final close, powered almost entirely by QIB, reflects deep institutional confidence in Molbio's business, backed by its WHO-recommended TB testing technology, patents across more than 100 countries, and a strong anchor book that had already featured names like Goldman Sachs, BlackRock, and IFC ahead of the issue opening.
Molbio Diagnostics IPO Subscription Status – Day 3 & Final
With bidding now closed, Molbio Diagnostics' IPO has finished as one of the most heavily oversubscribed mainboard IPOs of the current cycle, driven overwhelmingly by an extraordinary QIB surge in the final hours. Attention now turns to the allotment process, expected on August 13, and to how the stock performs on its August 17 listing.
Molbio Diagnostics IPO - Allotment and Listing Date
| Event | Date |
| Basis of Allotment | August 13, 2026 |
| Refund Initiation | August 14, 2026 |
| Shares Credited to Demat | August 13–14, 2026 |
| Listing Date | August 17, 2026 |
Should You Apply for Molbio Diagnostics IPO?
Since bidding has now closed, here's a look back at what shaped the issue:
- It's a mix of fresh issue and offer for sale, with the ₹200 crore fresh issue going toward R&D infrastructure and a Centre of Excellence under subsidiary Bigtec, while the larger ₹739.70 crore OFS portion went to existing shareholders exiting part of their stake.
- FY26 revenue rose 42% year-on-year, though profit after tax grew a more modest 18%, suggesting some margin pressure even as the top line scaled up strongly.
- Molbio holds a distinctive position in India's diagnostics space, with WHO-recommended TB testing technology and patent protection across more than 100 countries.
- The issue closed subscribed 70.26 times overall, with QIB at an extraordinary 186.39x, NII at 49.80x, retail at 12.98x, and the employee quota at 13.28x, reflecting overwhelming institutional conviction alongside strong broad-based demand.
- Given the scale of oversubscription, allotment will almost certainly be decided by lottery across every category, and the odds of receiving shares, even for one lot, will be slim.
This is informational content, not investment advice.
How to Apply for Molbio Diagnostics IPO
Bidding for this issue has now closed. If you missed the window, keep an eye on the listing date to evaluate the stock from the secondary market instead.
Molbio Diagnostics IPO Important Dates
| Event | Date |
| IPO Open Date | August 10, 2026 |
| IPO Close Date | August 12, 2026 |
| Basis of Allotment | August 13, 2026 |
| Refunds Initiated | August 14, 2026 |
| Demat Credit | August 13–14, 2026 |
| Listing Date | August 17, 2026 |
Day 2 & Day 3 Subscription Updates
Day 2 closed at 3.11x overall, with every category already oversubscribed. Day 3, the final day, saw an extraordinary surge, closing the issue at 70.26x overall, driven almost entirely by QIB (186.39x).
How to Check Molbio Diagnostics IPO Subscription Status
How to check Molbio Diagnostics IPO Subscription Status on NSE website
- Go to the NSE India website and open the "Live IPO Bidding" section.
- Select Molbio Diagnostics Limited from the dropdown.
- You'll see the final category-wise bid numbers for the closed issue.
How to check Molbio Diagnostics IPO Subscription Status on BSE website
- Visit the BSE India IPO page.
- Search for Molbio Diagnostics under recently closed issues.
- Click on it to view final bid quantity against shares reserved, split by category.
How to check Molbio Diagnostics IPO Subscription Status on Ventura?
Log into your Ventura account, go to the IPO section, and select Molbio Diagnostics from the list of recent issues. You'll find the final subscription numbers along with your own application status.
IPO Subscription History
Previous Day Subscription
Day 1 closed with the issue subscribed 0.67 times overall, building through the session from a slow morning start. Day 2 climbed to 3.11x overall, with every category, QIB, NII, retail, and employee, already past full subscription.
Final Subscription Figures
The issue closed subscribed 70.26 times overall. QIB closed at 186.39x, NII at 49.80x (bNII 50.82x, sNII 47.76x), retail at 12.98x, and the employee quota at 13.28x.
Conclusion
Molbio Diagnostics' IPO has closed out its bidding window in dramatic fashion, surging from 3.11x on Day 2 to 70.26x by the final close, powered by an extraordinary QIB rush past 186 times subscription. NII, retail, and the employee quota all closed comfortably oversubscribed as well. Backed by a strong anchor book featuring Goldman Sachs, BlackRock, and IFC, and a distinctive, globally patented position in India's diagnostics industry, this issue has closed as one of the standout mainboard IPOs of the current cycle, heading into its August 17 listing.
